Close Menu

Precipio

Researchers from Duke University's Center for Human Genome Variation and the International Serious Adverse Events Consortium plan to use whole-genome sequencing to find rare variants involved with an adverse drug event called clozapine-induced agranulocytosis.

Intrexon uses modular DNA control systems to enhance capabilities, improve safety, and lower cost in human therapeutics, protein production, industrial enzymes, and agriculture.

In the latter part of December, Clinical Data’s PGxHealth division inked a research collaboration with the German Heart Institute to “conduct one of the largest retrospective case/control studies to date to validate genetic variants associated with response” to Plavix. With this study, the partners hope to further inform the clinical utility of a pharmacogenetic test in determining best-responders to the anti-platelet agent.

The partners will evaluate and identify markers associated with response to the antiplatelet agent clopidogrel (Plavix).

The companies will evaluate the ability of Transgenomic's mitochondrial mutation-detection technology to detect and quantify the mutations for use in a possible diagnostic test.

Roche's cobas 4800 for HPV, CT, and NG; BD's ProbeTec Qx Amplified DNA Assays, Transgenomic's Surveyor Scan KRAS kit

In launching its Surveyor Scan KRAS mutation detection kit, Transgenomic will take on DxS' KRAS test, which is being globally marketed by Roche.

Pairings: Dec 2, 2009

Premium

Michael Lutz, Sidney Stolz, Scott Glenn

The firm saw a revenue boost from sales of its Familion genetic tests from its PGx Health division.

The firm trimmed its losses and selling costs, and it expects to launch a K-Ras test shortly.

Pages

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.